Clinical Trial Update: An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating two dosing regimens of BCD-085 for moderate to severe plaque psoriasis; study completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• To Severe Plaque Psoriasis

Drugs mentioned

• BCD-085

Snippet

Sponsor: Biocad | Conditions: Moderate to Severe Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2021-05-11